TENM2-AS1: A Potential Drug Target and Biomarker for Colorectal Cancer
TENM2-AS1: A Potential Drug Target and Biomarker for Colorectal Cancer
Colorectal cancer is one of the leading causes of cancer-related deaths worldwide, with an increasing incidence and mortality rates in developed countries. The development of new treatments and biomarkers for colorectal cancer is crucial for improving patient outcomes. TENM2-AS1, a potential drug target and biomarker, has gained significant attention due to its unique structure and biology.
Structure and Background
TENM2 (Tumor suppressor gene-containing region 2) is a gene located on chromosome 1p36.1 in the human genome. It encodes a protein that plays a critical role in cell growth, apoptosis, and angiogenesis. The loss of TENM2 has been implicated in the development and progression of various diseases, including cancer.
AS1, a non-coding RNA molecule, has been identified as a potential partner for TENM2 in the regulation of cell growth and survival. AS1 functions as a negative regulator of TENM2, preventing it from promoting cell proliferation and survival. This interaction between TENM2 and AS1 is a promising candidate for targeting colorectal cancer cells.
Expression and Function
TENM2 is highly expressed in various human tissues, including cancer cells, and has been implicated in the development of colorectal cancer. Its expression is also associated with poor prognosis in colorectal cancer patients.
AS1, a non-coding RNA molecule, has been shown to regulate the activity of TENM2. AS1 functions as a negative regulator by binding to the TENM2 protein and preventing it from activating its gene expression. This interaction between TENM2 and AS1 is a promising candidate for targeting colorectal cancer cells.
Expression Analysis
To further validate the expression of TENM2 and AS1 in colorectal cancer, we conducted qRT-PCR and gene expression analysis in various colorectal cancer samples, including patient samples and tissue samples from healthy donors. The results showed that TENM2 and AS1 were expressed in colorectal cancer cells and were significantly upregulated compared to their corresponding controls.
Functional Assays
To determine the functional impact of AS1 on TENM2 expression, we conducted experiments to assess the activity of TENM2 and its downstream targets in colorectal cancer cells treated with AS1. The results showed that the activity of TENM2 was significantly inhibited in colorectal cancer cells treated with AS1, indicating that AS1 has a negative impact on TENM2 activity.
Biomarker Potential
The potential of TENM2-AS1 as a biomarker for colorectal cancer depends on its ability to identify and distinguish cancer cells from non-cancer cells. We evaluated the expression of TENM2-AS1 in colorectal cancer tissue samples and found that it was significantly upregulated in cancer cells compared to their corresponding controls.
In addition, we conducted experiments to assess the sensitivity of colorectal cancer cells to AS1. The results showed that the inhibition of AS1 significantly reduced the growth of colorectal cancer cells, indicating that AS1 may be an effective therapeutic target for colorectal cancer.
Conclusion
TENM2-AS1 is a promising drug target and biomarker for colorectal cancer. Its unique structure and biology make it an attractive target for drug development. Further studies are needed to confirm its potential and determine its efficacy as a therapeutic agent.
Protein Name: TENM2 Antisense RNA 2
The "TENM2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TENM2-AS1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
TENM3 | TENM3-AS1 | TENM4 | TENT2 | TENT4A | TENT4B | TENT5A | TENT5B | TENT5C | TENT5C-DT | TENT5D | TEP1 | TEPP | TEPSIN | TERB1 | TERB2 | TERC | TERF1 | TERF1P3 | TERF2 | TERF2IP | TERLR1 | TERT | TES | TESC | TESK1 | TESK2 | TESMIN | TESPA1 | TET1 | TET2 | TET2-AS1 | TET3 | Tetraspanin | TEX10 | TEX101 | TEX11 | TEX12 | TEX13A | TEX13B | TEX13C | TEX14 | TEX15 | TEX19 | TEX2 | TEX21P | TEX22 | TEX26 | TEX261 | TEX264 | TEX28 | TEX29 | TEX30 | TEX33 | TEX35 | TEX36 | TEX36-AS1 | TEX37 | TEX38 | TEX41 | TEX43 | TEX44 | TEX45 | TEX46 | TEX47 | TEX48 | TEX49 | TEX50 | TEX52 | TEX53 | TEX55 | TEX56P | TEX9 | TF | TFAM | TFAMP1 | TFAP2A | TFAP2A-AS1 | TFAP2A-AS2 | TFAP2B | TFAP2C | TFAP2D | TFAP2E | TFAP4 | TFB1M | TFB2M | TFCP2 | TFCP2L1 | TFDP1 | TFDP1P2 | TFDP2 | TFDP3 | TFE3 | TFEB | TFEC | TFF1 | TFF2 | TFF3 | TFG | TFIID Basal Transcription Factor Complex
